期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非诺贝特抑制血管紧张素Ⅱ所诱导的心脏成纤维细胞骨桥蛋白表达升高 被引量：5

Inhibition of fenofibrate on angiotensinⅡ-induced high expression of osteopontin in cardiac fibroblasts
在线阅读 下载PDF
导出
摘要 目的:探讨过氧化物酶体增殖物激活受体α(PPARα)激动剂非诺贝特对血管紧张素Ⅱ(An-gⅡ)诱导的心脏成纤维细胞骨桥蛋白表达升高的影响。方法:分离并传代培养SD大鼠乳鼠心脏成纤维细胞,使用不同浓度(0、25、50、100μmol/L)的非诺贝特预处理1h后,加入An-gⅡ作用24h。分别采用实时定量PCR法和Western blotting技术检测骨桥蛋白mRNA和蛋白表达情况。结果:非诺贝特显著抑制AngII诱导的心脏成纤维细胞骨桥蛋白mRNA及蛋白的表达,并且呈剂量依赖性。结论:非诺贝特对心脏成纤维细胞中骨桥蛋白的表达具有明显的抑制作用,这可能是其在心血管系统发挥抗纤维化和抗炎作用的部分机制。 AIM：To investigate the effects of fenofibrate,peroxisome proliferator-activated receptor α（PPARα） agonist,on the up-regulation of angiotensin II（Ang II）-induced osteopontin in rat cardiac fibroblasts. METHODS：Isolated cardiac fibroblasts of neonatal Sprague-Dawley rat were pretreated with various concentrations of fenofibrate（0,25,50 and 100 μmmol/L） for 1 hour.Then Ang II were added into cells for 24 hours.The expression of osteopontin was measured by real-time quantitative RT-PCR and Western blotting,separately.RESULTS：Significant inhibitory effects of fenofibrate on Ang II-induced high expression of osteopontin were observed in cardiac fibroblasts and the effect was dose dependent（P0.05）.CONCLUSION：The present data suggests that fenofibrate can down-regulate the level of osteopontin in rat cardiac fibroblasts,which may explain the anti-inflammatory and anti-fibrosis effects of fenofibrate in the cardiovascular system.
作者 李文举 石苗茜 欧东波 丁璐 牛晓琳 刘雄涛 郑强荪
机构地区 第四军医大学唐都医院心内科
出处 《中国临床药理学与治疗学》 CAS CSCD 2010年第11期1211-1215,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 心肌纤维化 心脏成纤维细胞 非诺贝特 骨桥蛋白 Myocardial fibrosis Cardiac fibroblast Fenofibrate Osteopontin
分类号 R965.2 [医药卫生—药理学]
  • 相关文献

参考文献19

  • 1曾爱辉,谭茗月.骨桥蛋白与慢性心力衰竭的关系研究进展[J].中国现代药物应用,2009,3(18):183-185. 被引量：5
  • 2李传保,卜培莉.非诺贝特与高血压心肌重构[J].中国老年学杂志,2008,28(1):100-102. 被引量：3
  • 3Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer [J]. Clin Cancer Res, 2004, 10(5): 1588--1596.
  • 4Livak K J, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) Method [J]. Methods, 2001, 25(4):402-408.
  • 5Vera T, Taylor M, Bohman Q, et al. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice [J]. Hypertension, 2005, 45(4) : 730-735.
  • 6Wang Y, Wang Y, Yang Q, et al. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells[J]. Atherosclerosis, 2006, 187 (2) : 265--273.
  • 7Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors [J]. Mol Cell Cardiol, 2006, 41(2): 318-329.
  • 8Brigadeau F, Gele P, Wibaux M, et al. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy [J]. J Cardiovasc Pharmacol, 2007, 49(6): 408-415.
  • 9Lebrasseur NK, Duhaney TA, De Silva DS, et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension [J]. Hypertension, 2007, 50(3): 489-496.
  • 10Ogata T, Miyauchi T, Irukayama-Tomobe Y, et al. The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation[J]. J Cardiovase Pharmacol, 2004, 44 Suppl 1: S279-282.

二级参考文献52

  • 1臧敬五.自身免疫性疾病研究的新进展——骨桥蛋白在类风湿性关节炎中的病理机制研究[J].中国科学院院刊,2005,20(3):208-210. 被引量：53
  • 2Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg- Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA, 1986, 83 : 8819-8823.
  • 3Malta Scatena, Lucy Liaw, Cecilia M. Osteopontin :A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular. Biology, 2007, 27 : 2302 -2309.
  • 4Mark W. M. Schellings, Yigal M. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res, 2004 Oct 1,64( 1 ) :24-31.
  • 5Takemoto M , Yokote K, Yamazaki M , et al . Enhaneed expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Bio chem Bio phys Res Commun, 1999, 258: 722- 726.
  • 6David T, Denhardt, Masaki Noda, et al Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest,2001 May 1,107(9) : 1055-1061.
  • 7O' Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb, 1994,14 : 1648-1656.
  • 8Yutaka Matsui, Nan Jia, Hiroshi Okamoto, et al. Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II-Induced Cardiac Hypertrophy. Hypertension,2004 ;43 : 1195.
  • 9Collins AR, Schnee J, Wang W, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coil Cardiol,2004,43 : 1698-1705.
  • 10Nathan A. Trueblood, Zhonglin Xie. Exaggerated Left Ventricular Dilation and Reduced Collagen Deposition After Myocardial Infarction in Mice Lacking Osteopontin. Circulation Research, 2001,88 : 1080-1087.

共引文献7

同被引文献61

  • 1吴静.调脂药物的一支独秀——非诺贝特的独特作用及其临床应用[J].实用糖尿病杂志,2005,1(5):59-61. 被引量：18
  • 2陈维杰,柳亚峰,曲娜,张淑华.急性心肌梗死后心室重塑的发生机制探讨及其临床意义[J].中国急救医学,2006,26(10):697-698. 被引量：3
  • 3曾定尹.心力衰竭[M]//王吉耀,内科学(8年制教材).北京:人民卫生出版社.2005:187.
  • 4Ogata T, Miyauchi T, Irukayama Tomobe Y, et al. The peroxisome proliferator activated receptor alpha activator fenofibrate inhibits endothelin-1induced cardiac fibroblast proliferation [J].J Cardiovasc Pharmacol, 2004 ;44 ( Suppll ) : S279-83.
  • 5LeBrasseur NK, Duhaney TAS, De Silva DS, et al. Effects of fenofibrate on cardiac remodeling in aldosterone induced hypertension [J]. Hypertension, 2007 ;50 ( 3 ) :489 -95.
  • 6lchihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down regulation of redox regulated transcription factors[J]. J Mol Cell Cardiol,2006 ;41 (2) :318-22.
  • 7Diep QN, Benkiran K, Amiri F,et al. PPARct activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin Ⅱ-infused rats[J]. J Mol Cell Cardio ,2004 ; 36 ( 2 ) :295-9.
  • 8Huang WP, Yin WH, Chen JW, et al. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study [J]. Eur J Clini Invest,2009 ;39(9) :775-9.
  • 9Leyva F,Anker SD,Godsland IF,et al. Uric acid in chronic heart failure:a marker of chronic inflammation [J]. Eur Heart J, 1998;19 (12) :1814-22.
  • 10Landmesser U, Spiekermann S, Dikalov S,et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure : role of xanthine oxidase and extracellular superoxide dismutase [J]. Circulation,2002 ; 106 : 3073-8.

引证文献5

二级引证文献14

中国临床药理学与治疗学
2010年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部